A phase 3 clinical trial of the BTK inhibitor, tolebrutinib, has shown a reduction in disability accumulation in people with non-relapsing secondary progressive MS.
MS Australia supports a proposal to allow nurse practitioners to prescribe key MS medications, improving access to care in underserved areas. The PBAC will review the proposal in November 2024.
The Multiple Sclerosis Journal has published the next iteration of The Pathways to Cures Roadmap, which outlines research areas with the greatest potential to stop MS, restore function and repair damage from the disease, and end MS through prevention.
CEO Rohan Greenland reflects on the 20th anniversary of MS Australia’s national MS research program, a program which has helped supercharge Australian research and boosted collaboration across the sector.
New study reveals key workplace factors linked to unemployment risk in people with MS.
Two-time Paralympian Emily Petricola and first-time Paralympian Ameera Lee share what it means to wear Green and Gold in the upcoming Paris Paralympic Games, while living with MS.
A new Australian study has found that lower doses of rituximab may be an effective and safe treatment for NMOSD.
Researchers develop new molecule to boost myelin repair in MS.
In November 2024, the Pharmaceutical Benefits Advisory Committee (PBAC) will meet to consider a proposal to recommend adding ravulizumab (Ultomiris®) to the Pharmaceutical Benefits Scheme (PBS) for adults with NMOSD.
